AVR · Anteris Technologies Global Corp. · Stock research

Current Thesis

Anteris is a clinical-stage structural-heart company, dual-listed ASX:AVR / NASDAQ:AVR, built around DurAVR — a single-piece, 3D-shaped biomimetic transcatheter aortic valve now enrolling the US-pivotal PARADIGM trial (~1,000 patients, 1:1 versus commercial TAVR, non-inferiority composite of all-cause mortality, all stroke and CV hospitalization at one year). The de-risking sequence that powered the multi-quarter run is finished: CMS Coverage-with-Evidence-Development under NCD 20.32 (2026-04-28), first US patients at Montefiore (2026-05-05, Dr. Azeem Latib), and full French ANSM clearance (2026-06-08). Each moved enrollment forward without delivering trial data. Since the French clearance the tape has carried the story alone — price pushed to a fresh 52-week high near $11.06, then gave back roughly 11% to $9.77 by the July 10 close on no news, settling back onto the $9.00 TD Cowen ATM reference. Fifteen sessions later the picture is unchanged: no new narrative fuel, a live in-the-money $250M dilution shelf at the level price is retesting from above, and the real value inflection — PARADIGM's one-year endpoint — parked around 2028 with enrollment finishing ~Q1 2027. A genuine disruptor carrying Strong-Buy sell-side and ~64% of upside to the $16 average target, but the near-term move is price-led, not narrative-led. Maturing and idiosyncratic; a low-conviction watch that does not yet justify a fresh entry.

Bullish and bearish views on Anteris Technologies Global Corp.

The model's bull view on Anteris Technologies Global Corp. (AVR), in brief: Pivotal trial live and geographically broadening — full French ANSM clearance (2026-06-08) opened recruitment at experienced French centers on top of active US/EU sites; first US patients treated 2026-05-05 (Montefiore, Dr. Latib). The bear view: The $250M ATM is an in-the-money seller into the fade. Both cases follow in full.

Bull Case

• Pivotal trial live and geographically broadening — full French ANSM clearance (2026-06-08) opened recruitment at experienced French centers on top of active US/EU sites; first US patients treated 2026-05-05 (Montefiore, Dr. Latib). PARADIGM is ~1,000 patients, 1:1 DurAVR versus commercial TAVR, one-year non-inferiority composite.
• Reimbursement cleared before scale-up — CMS Coverage-with-Evidence-Development under NCD 20.32 approved 2026-04-28; US site activation followed within a week, removing the largest US trial-execution risk ahead of the enrollment ramp.
• Incumbent strategic capital — Covidien (Medtronic subsidiary) committed up to $90M for 16–19.99% of post-offering shares, closed 2026-01-22 alongside a $230M public raise ($320M aggregate). An incumbent funding a competing valve platform is a real endorsement.
• Sell-side leaning in — consensus Strong/Moderate Buy, average PT $16.00 (~64% above the $9.77 close): Barclays Overweight PT $18 (2026-05-15), Wells Fargo Overweight PT $16 (2026-03-11), Cantor Overweight PT $15 (2026-03-27).
• Funded through enrollment — the January raise plus the $250M ATM cover the ~$28.7M/qtr burn with no near-term financing cliff; market cap ~$951M as of 2026-07-10.

Bear Case

• The $250M ATM is an in-the-money seller into the fade. TD Securities sales agreement dated 2026-05-22, up to $250M (~26–28M shares, ~27% of the ~97M count) at 3.0% commission. Above $9 the company can issue directly into strength — the facility manufactures supply at exactly the level the chart is now retesting from above.
• The momentum leg stalled with nothing behind it. New high near $11.06, then ~11% back to $9.77 by 2026-07-10 on no news. CMS, first-patient and French clearance are complete and were enrollment-pace steps; the one-year binary sits around 2028 with enrollment finishing ~Q1 2027. No dated data catalyst inside 30 days.
• Pre-revenue with deep losses — 2025 net loss $94.14M on $1.91M revenue (−29% YoY); Q1 2026 net cash outflow $28.7M ($17.5M to R&D), EPS $(0.28) missed by a penny, sales $494K vs ~$767K est. Any clinical hiccup is asymmetric downside.
• No peer cluster confirming. TAVR incumbents Edwards Lifesciences, Medtronic and Boston Scientific are mega-caps that are range-bound, not breaking out together; there is no small-cap structural-heart disruptor cohort moving in sympathy. Strength is idiosyncratic and thin.
• Medtronic sits on both sides — the Covidien stake sits beside Medtronic's incumbent TAVR franchise, so the relationship cuts both ways and could cap strategic optionality even as it validates the platform.

Setup & Price Structure

The 2026-06-08 French clearance marked the last narrative fuel; price extended to ~$11.06, a fresh 52-week high, then rolled over ~11% to $9.77 at the 2026-07-10 close ($9.99 after-hours) with no accompanying news. That fade dropped it straight onto the $9.00 TD Cowen ATM reference, a level that flips character with the tape: a reclaimed pivot while price holds above it, a supply ceiling the moment it cannot. Because the rally to new highs arrived without a catalyst, the whole read reduces to whether $9 holds on a closing basis. A break there returns price beneath the ATM strike and the dilution shelf and stamps the June–July high as a failed breakout; holding it keeps the reclaimed-pivot read alive but does not, on its own, create a reason to chase an extended single name with no near-term binary and no peers confirming. This is a name to let base rather than chase into a stalled, idiosyncratic leg.

Catalyst Calendar (next 30 days)

• No data readout in the window. PARADIGM's one-year primary endpoint is ~2028 and enrollment completes ~Q1 2027. Interim enrollment or site-expansion press releases are possible but unscheduled.

Elapsed catalysts

• ~2026-07-31 (est.) — Appendix 4C quarterly cash-flow report (quarter ended 2026-06-30) on ASX. The key read is ATM-draw pace and cash burn against the ~$28.7M/qtr Q1 outflow; heavy issuance disclosed here would confirm the seller is active near $9. (passed 9d ago)
• ~mid-August 2026 (est.) — Q2 results (Q1 reported 2026-05-12). Pre-revenue print; the watch items are cash runway, R&D spend and PARADIGM enrollment commentary rather than the P&L lines. (passed 89d ago)

What Would Change Our Mind

A weekly close below $9.00 loses the reclaimed TD Cowen ATM reference, puts price back under the dilution shelf, and confirms the June–July high as a failed breakout — that ends the constructive read. Secondary breaks: an 8-K or Appendix 4C disclosing heavy ATM issuance into the fade (supply arriving near $9), or any PARADIGM enrollment halt or safety signal. On the constructive side, the low-conviction stance would upgrade on a fresh dated catalyst — an interim enrollment milestone, a data-readout date pulled forward, or a structural-heart disruptor cluster breaking out together — that converts an idiosyncratic momentum name into a narrative with peers behind it.

Correlation Notes

AVR trades on its own catalysts rather than as a theme vehicle. The TAVR reference set — Edwards Lifesciences, Medtronic, Boston Scientific — is mega-cap and range-bound, so the disruptor does not inherit a group bid, and there is no small-cap structural-heart cohort moving with it. The ASX:AVR session leads the US tape, so overnight Australian price action and the Appendix 4C filing set the US open. Medtronic is a dual node — strategic investor via Covidien and incumbent competitor — so Medtronic capital-markets or TAVR-franchise news can push AVR either way. Broad medtech-device beta and biotech risk appetite matter at the margin, but the dominant near-term driver is the ATM seller's behavior around $9.